v3.24.0.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 1,123,604 $ 3,147,702
Unbilled receivable 97,561 276,821
Right-of-use asset 27,165
Prepaid expenses and other current assets 1,067,703 1,847,481
Total current assets 2,288,868 5,299,169
Property and equipment, net
Other assets 419,217 585,883
Total assets 2,708,085 5,885,052
Current liabilities:    
Accounts payable 1,936,007 2,943,791
Accrued expenses and other liabilities 542,260 2,226,494
Lease liability 27,315
Notes payable and accrued interest 854,697 4,266,610
Total current liabilities 3,332,964 9,464,210
Long-term liabilities:    
Notes payable, net of current portion (at fair value) 140,148
Other long-term liabilities 26,388 310,346
Total long-term liabilities 26,388 450,494
Total liabilities 3,359,352 9,914,704
Commitments and contingencies (Note 6)
Preferred stock, $0.0001 par value, 1,500,000 shares authorized, no shares issued and outstanding at December 31, 2023 and December 31, 2022
Common stock, $0.0001 par value, 250,000,000 shares authorized at December 31, 2023 and December 31, 2022; 3,146,157 and 534,571 shares issued at December 31, 2023 and December 31, 2022, respectively; 3,146,076 and 534,490 shares outstanding at December 31, 2023 and December 31, 2022, respectively 315 53
Additional paid-in capital 121,233,901 107,216,566
Accumulated deficit (121,557,074) (110,931,063)
Total Ensysce Biosciences, Inc. stockholders’ deficit (322,858) (3,714,444)
Noncontrolling interests in stockholders’ deficit (328,409) (315,208)
Total stockholders’ deficit (651,267) (4,029,652)
Total liabilities and stockholders’ deficit $ 2,708,085 $ 5,885,052

Source

PDF HTML
ZIP XLS XBRL